• MARVEL Trial Authors for the MARVEL Investigators, Qingwu Yang, Changwei Guo, Chengsong Yue, Jiaxing Song, Jie Yang, Zhouzhou Peng, Nizhen Yu, Jiacheng Huang, Linyu Li, Jiandi Huang, Yifei Chen, Chong Zheng, Shunfu Jiang, Zhongfan Ruan, Min Zhang, Dengwen Song, Xiaojun Luo, Yaoyu Tian, Mei Yang, Shenglin Deng, Shirong Wei, Youlin Wu, Yufeng Tang, De Yang, Xiaolin Tan, Guoyong Zeng, Daoyou Cheng, Wenhua Liu, Wencheng He, Tieying Cai, Chengde Pan, Jiasheng Liao, Bo Lei, Shengxiong Pu, Zhenglong Jin, Jinglun Li, Zhongbin Xia, Guling Zhang, Jun Luo, Yaxuan Sun, Xiaoping Xiong, Jian Wang, Bo Li, Yuqi Peng, Kechun Chen, Yuanjun Shan, Peiyang Zhou, Xinyuan Huang, Shiwei Luo, Jie Zhang, Chang Liu, Lin Jiang, Dahong Yang, Yan Tian, Jinrong Hu, Zhongming Qiu, Jinfu Ma, Xu Xu, Shitao Fan, Xiang Liu, Dongjing Xie, Jianqin Niu, Hongting Zheng, Qin Ouyang, Duolao Wang, Thanh N Nguyen, Jeffrey L Saver, Raul G Nogueira, Fengli Li, and Wenjie Zi.
• Department of Neurology, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
• JAMA. 2024 Mar 12; 331 (10): 840849840-849.

ImportanceIt is uncertain whether intravenous methylprednisolone improves outcomes for patients with acute ischemic stroke due to large-vessel occlusion (LVO) undergoing endovascular thrombectomy.ObjectiveTo assess the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for acute ischemic stroke secondary to LVO.Design, Setting, And ParticipantsThis investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 82 hospitals in China, enrolling 1680 patients with stroke and proximal intracranial LVO presenting within 24 hours of time last known to be well. Recruitment took place between February 9, 2022, and June 30, 2023, with a final follow-up on September 30, 2023.InterventionsEligible patients were randomly assigned to intravenous methylprednisolone (n = 839) at 2 mg/kg/d or placebo (n = 841) for 3 days adjunctive to endovascular thrombectomy.Main Outcomes And MeasuresThe primary efficacy outcome was disability level at 90 days as measured by the overall distribution of the modified Rankin Scale scores (range, 0 [no symptoms] to 6 [death]). The primary safety outcomes included mortality at 90 days and the incidence of symptomatic intracranial hemorrhage within 48 hours.ResultsAmong 1680 patients randomized (median age, 69 years; 727 female [43.3%]), 1673 (99.6%) completed the trial. The median 90-day modified Rankin Scale score was 3 (IQR, 1-5) in the methylprednisolone group vs 3 (IQR, 1-6) in the placebo group (adjusted generalized odds ratio for a lower level of disability, 1.10 [95% CI, 0.96-1.25]; P = .17). In the methylprednisolone group, there was a lower mortality rate (23.2% vs 28.5%; adjusted risk ratio, 0.84 [95% CI, 0.71-0.98]; P = .03) and a lower rate of symptomatic intracranial hemorrhage (8.6% vs 11.7%; adjusted risk ratio, 0.74 [95% CI, 0.55-0.99]; P = .04) compared with placebo.Conclusions And RelevanceAmong patients with acute ischemic stroke due to LVO undergoing endovascular thrombectomy, adjunctive methylprednisolone added to endovascular thrombectomy did not significantly improve the degree of overall disability.Trial RegistrationChiCTR.org.cn Identifier: ChiCTR2100051729.

17 keywords...

hide…